Press Releases (-) Any 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2022 October 27, 2022 argenx Reports Third Quarter 2022 Financial Results and Provides Business Update October 20, 2022 argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022 September 21, 2022 argenx Submits Biologics License Application to U.S. Food and Drug Administration for Subcutaneous Efgartigimod for Treatment of Generalized Myasthenia Gravis September 21, 2022 argenx to Highlight Key Programs from Neuromuscular Franchise at Upcoming Medical Meetings September 8, 2022 argenx Appoints Camilla Sylvest to Board of Directors August 31, 2022 argenx to Present at Wells Fargo Healthcare Conference August 11, 2022 argenx Announces European Commission Approval of VYVGART™ (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis July 28, 2022 argenx Reports Half Year 2022 Financial Results and Provides Second Quarter Business Update July 21, 2022 argenx to Report Half Year 2022 Financial Results and Second Quarter Business Update on July 28, 2022 June 24, 2022 argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe June 1, 2022 argenx to Present at Upcoming Investor Conferences May 31, 2022 argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized Myasthenia Gravis Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last »
